

# Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer

*Ther Adv Med Oncol*

2023, Vol. 15: 1

DOI: 10.1177/  
17588359231201818

© The Author(s), 2023.  
Article reuse guidelines:  
[sagepub.com/journals-  
permissions](https://sagepub.com/journals-permissions)

Slamon DJ, Fasching PA, Hurvitz S, *et al.* Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. *Therapeutic Advances in Medical Oncology*. 2023; 15. doi:10.1177/17588359231178125.

In the original published version of this paper, Figure 3 incorrectly depicted the inclusion criteria for the monarchE trial with respect to patients with Stage III N1 disease. Figure 3 has now been updated to accurately depict the inclusion of patients with Stage III N1 disease in the monarchE trial.

Visit Sage journals online  
[journals.sagepub.com/  
home/tam](https://journals.sagepub.com/home/tam)

 Sage journals

